CytomX Therapeutics Announces Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
CytomX Therapeutics (CTMX) Reports FY18 Loss of $2.03
February 27, 2019 4:51 PM ESTCytomX Therapeutics (NASDAQ: CTMX) reported FY18 EPS of ($2.03), versus ($1.16) reported last year. Revenue for the quarter came in at $59.5 million, versus $71.6 million reported last year.
Cash, cash equivalents and short-term investments totaled $436.1 million as of December 31, 2018, compared to $374.1 million as of December 31,... More
